Benefits
Iron absorption in women with low iron stores
In 17 young women with low iron stores, meat pate fortified with Lipofer raised blood iron over the next 6 hours about as much as the same pate fortified with ferrous sulfate. This single-meal study measured blood iron only, not iron stores or symptoms, and was supported by the pate maker.
Restored iron levels in iron-deficient rats
In iron-deficient rats given an amount equal to 80 mg of iron a day for a person, Lipofer reversed the deficiency within 14 days, as did ferrous sulfate, ferrous bisglycinate and another encapsulated iron. Blood markers suggested Lipofer was absorbed better than the other encapsulated iron. This was a maker-funded animal study, not a human trial.
Gut tolerance in an animal model
Over 9 weeks of dosing in rats, stool water, weight and frequency did not differ between Lipofer and any other iron source, including ferrous sulfate. Ferrous sulfate raised a gene marker of colon inflammation (IL-6) and Lipofer did not. Whether this means fewer stomach complaints in people has not been tested.
Daily iron in menstruating women (other iron forms)
Lipofer has not been tested as a daily supplement in women. Across 67 trials in menstruating women, daily iron supplements of various forms lowered the risk of anaemia and iron deficiency and raised haemoglobin, though they also caused more digestive side effects. Extra iron only helps when stores are low, which a blood test can confirm.
Encapsulated for use in fortified foods
Encapsulation keeps the iron from interacting with other ingredients and is meant to improve stability and taste. Lipofer has been tested as the iron source in a fortified meat pate in women, and in fortified wheat flour in a laboratory digestion model.
Mechanism of action
Protected delivery
The encapsulation shields the iron from interacting with food and the gut lining until it is absorbed, which is proposed to lower side effects. This has been examined only in rats.
Hemoglobin synthesis
Absorbed iron is used to build hemoglobin and myoglobin, supporting oxygen transport and energy metabolism.
Clinical trials
Animal study comparing Lipofer with ferrous sulfate, ferrous bisglycinate and another microencapsulated ferric pyrophosphate in rats made iron-deficient by diet, at a dose equal to 80 mg of elemental iron a day for a person, over a 21-day repletion phase and 9 weeks of tolerance testing. Funded by Lubrizol Nutraceuticals. (Mariné-Casadó et al. 2025, Scientific Reports)
Iron-deficient rats; not a human study.
All four iron sources reversed iron deficiency within 14 days. Lipofer gave lower TIBC and transferrin and higher haemoglobin than the other microencapsulated iron, which the authors read as better absorption. Stool water, weight and frequency did not differ between any groups. Ferrous sulfate raised IL-6 gene expression in the colon and Lipofer did not. Two authors work for Lubrizol Nutraceuticals, which funded the study and supplied the products.
Randomized, double-blind, three-way crossover single-meal study comparing pate with 15 mg of added iron as ferrous sulfate, as liposome-encapsulated ferric pyrophosphate (Lipofer), or as Lipofer plus a haem-rich meat pigment; blood iron measured hourly for 6 hours. (Navas-Carretero et al. 2009, Nutrition)
17 young women in Spain with ferritin below 30 ug/L.
The rise in blood iron over 6 hours did not differ between the three meals, peaking at 2 to 4 hours. Only a single meal was tested, with no measure of iron stores, symptoms or side effects. The study was supported by the pate maker and the Spanish Ministry of Education and Science.